CCM
SNDX icon

Coldstream Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Coldstream Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47
Closed -$579 – 3025
2025
Q1 		$579 Buy
+47
New +$663 ﹤0.01% 3315

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Coldstream Capital Management's SNDX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 47 shares — an estimated $579 sold.

Coldstream Capital Management first reported a position in SNDX in Q1 2025 and held it in 1 quarter. The position peaked at $579 in Q1 2025. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 47 Syndax Pharmaceuticals shares in Q2 2025, an estimated $579.
  • Coldstream Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Syndax Pharmaceuticals position peaked at $579 in Q1 2025.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.